Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07678593 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Primary endpoints: details revised at 1 of 10 entries · Eligibility criteria expanded, about 20 words · Site details revised at 17 of 17 sites Show 3 more changesShow less
    • Primary endpoints: details revised at 1 of 10 entries
    • Eligibility criteria expanded, about 20 words
    • Site details revised at 17 of 17 sites
  2. Trial sites expanded: 3 → 17 locationsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Trial Details
NCT Number NCT07678593
Lead Sponsor Genfleet Therapeutics (Shanghai) Inc.
Conditions Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
Enrollment 222 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov